文献速递心力衰竭与心肌病心律失常

血浆大内皮素-1对左心室心肌致密化不全心肌病的预后价值

Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy.
PubMed 文献 · Heart · 2020-10-14

该前瞻性队列纳入203例经心脏磁共振确诊且有大内皮素-1数据的左心室心肌致密化不全心肌病患者,按血浆大内皮素-1中位数0.42 pmol/L分为高、低两组,中位随访1.9年。Kaplan-Meier分析显示高组主要和次要终点风险均更高,校正混杂因素后Ln大内皮素-1为复合主要终点的独立预测因子(HR 1.83,95%CI 1.27-2.62,p=0.001)。

要点

  • 血浆大内皮素-1≥0.42 pmol/L的LVNC患者主要和次要终点风险显著更高。
  • Ln大内皮素-1是复合主要终点的独立预测因子(HR 1.83,95%CI 1.27-2.62)。
  • Ln大内皮素-1预测主要终点的C统计量为0.755(95%CI 0.685-0.824)。

核心结论

  • 血浆大内皮素-1可能是预测左心室心肌致密化不全心肌病患者临床不良结局的有价值指标。

研究设计与样本

  • 前瞻性纳入203例经心脏磁共振确诊且有大内皮素-1数据的左心室心肌致密化不全心肌病患者,中位年龄44岁,男性占70.9%。

主要发现

  • 按血浆大内皮素-1中位数0.42 pmol/L分为高水平和低水平组,中位随访1.9年(IQR 0.9-3.1年)。
  • Kaplan-Meier分析显示高水平组较低水平组主要终点和次要终点风险均更高(均p<0.001)。
  • Ln大内皮素-1与Ln N末端脑钠肽前体、左心室直径正相关,与年龄和Ln左心室射血分数负相关。
  • 校正混杂因素后,Ln大内皮素-1是复合主要终点的独立预测因子(HR 1.83,95%CI 1.27-2.62,p=0.001)。
  • 校正混杂因素后,Ln大内皮素-1是次要终点的独立预测因子(HR 1.93,95%CI 1.32-2.83,p=0.001)。

关键数值与推荐

  • 主要终点为全因死亡、心脏移植、持续性室性心动过速/心室颤动和植入式心律转复除颤器放电的复合终点。
  • 次要终点为心源性死亡或心脏移植。
  • Ln大内皮素-1预测主要终点的C统计量为0.755(95%CI 0.685-0.824,p<0.001)。

临床怎么用

  • 对左心室心肌致密化不全心肌病患者可检测血浆大内皮素-1,高水平(≥0.42 pmol/L)提示不良预后风险增高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the prognostic role of big endothelin-1 (ET-1) in left ventricular non-compaction cardiomyopathy (LVNC). METHODS: We prospectively enrolled patients whose LVNC was diagnosed by cardiac MRI and who had big ET-1 data available. Primary end point was a composite of all-cause mortality, heart transplantation, sustained ventricular tachycardia/fibrillation and implanted cardioverter defibrillator discharge. Secondary end point was cardiac death or heart transplantation. RESULTS: Altogether, 203 patients (median age 44 years; 70.9% male) were divided into high-level (≥0.42 pmol/L) and low-level (<0.42 pmol/L) big ET-1 groups according to the median value of plasma big ET-1 levels. Ln big ET-1 was positively associated with Ln N-terminal pro-brain natriuretic peptide, left ventricular diameter, but negatively related to age and Ln left ventricular ejection fraction. Median follow-up was 1.9 years (IQR 0.9-3.1 years). Kaplan-Meier analysis showed that, compared with patients with low levels of big ET-1, those with high levels were at greater risk for meeting both primary (p<0.001) and secondary (p<0.001) end points. The C-statistic estimation of Ln big ET-1 for predicting the primary outcome was 0.755 (95% CI 0.685 to 0.824, p<0.001). After adjusting for confounding factors, Ln big ET-1 was identified as an independent predictor of the composite primary outcome (HR 1.83, 95% CI 1.27 to 2.62, p=0.001) and secondary outcome (HR 1.93, 95% CI 1.32 to 2.83, p=0.001). CONCLUSIONS: Plasma big ET-1 may be a valuable index to predict the clinical adverse outcomes in patients with LVNC.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Fan P, Zhang Y, Lu YT, et al. Prognostic value of plasma big endothelin-1 in left ventricular non-compaction cardiomyopathy. Heart. 2020. PMID: 33055147. doi:10.1136/heartjnl-2020-317059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。